Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

Wang,Chao; Kang,Le; Wang,Xipeng; Liu,Yanping; Zhao,Xia

doi:10.3892/ol.2018.8063

Expression of miR-200a and chemotherapeutic treatment efficacy of glioma

Authors:
- Chao Wang
- Le Kang
- Xipeng Wang
- Yanping Liu
- Xia Zhao
View Affiliations

Affiliations: Emergency Intensive Care Unit, The Sixth People's Hospital of Jinan, Jinan, Shandong 250200, P.R. China, Operating Room, The Sixth People's Hospital of Jinan, Jinan, Shandong 250200, P.R. China, Department of General Surgery, The Sixth People's Hospital of Jinan, Jinan, Shandong 250200, P.R. China, Department of Nursing, The Sixth People's Hospital of Jinan, Jinan, Shandong 250200, P.R. China
Published online on: February 15, 2018 https://doi.org/10.3892/ol.2018.8063
Pages: 5767-5771
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The correlation between miR-200a expression and chemotherapeutic treatment efficacy of glioma was investigated. There were 45 patients with glioma in observation group whose cancer tissues, paracancerous tissues and serum samples were harvested. Additionally, there were 23 healthy subjects in the control group whose serum samples were also collected. The expression levels of miR-200a in cancer tissues, paracancerous tissues and serum samples were measured by real-time fluorescence-based quantitative polymerase chain reaction (qRT-PCR). The t-test and one-way ANOVA were used to compare the serum levels of miR-200a in patients with different clinical features involving age, sex, tumor location, pathological grade and tumor size. All patients in the observation group received temozolomide-based chemotherapy. The serum levels of miR‑200a before chemotherapy were compared between patients who were responsive to chemotherapy [complete response (CR) and partial response (PR)] and patients who were not responsive to chemotherapy [stable disease (SD) and progressive disease (PD)]. The expression level of miR-200a in cancer tissue was significantly lower than that in paracancerous tissue (p<0.05). The serum level of miR-200a in patients in the observation group was lower than that in healthy subjects in the control group (p<0.05). No correlations were found between miR-200a expression and patient age, sex and tumor location (p>0.05), but miR-200a expression was found to correlate with pathological grade and tumor size (p<0.05). The expression levels of miR-200a in serum and cancer tissue in chemotherapy-non-responsive patients (SD and PD) were lower than those in chemotherapy-responsive patients (CR and PR, p<0.05). The serum levels of miR-200a in chemotherapy-responsive patients were lower than those in healthy subjects in the control group (p<0.05). Downregulation of miR-200a was associated with onset and progression of glioma, and changes of miR-200a expression levels in patients were correlated with chemotherapeutic treatment efficacy.

View Figures

View References

1	Bush NA, Chang SM and Berger MS: Current and future strategies for treatment of glioma. Neurosurg Rev. 40:1–14. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hempel JM, Schittenhelm J, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda VS, Ernemann U and Klose U: Effect of perfusion on diffusion kurtosis imaging estimates for in vivo assessment of integrated 2016 WHO glioma grades: A cross-sectional observational study. Clin Neuroradiol. 1-11:2017.https://doi.org/10.1007/s00062-017-0606-8
3	Feng X, Yu Y, He S, Cheng J, Gong Y, Zhang Z, Yang X, Xu B, Liu X, Li CY, et al: Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. Cancer Lett. 385:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
4	Madsen SJ, Christie C, Hong SJ, Trinidad A, Peng Q, Uzal FA and Hirschberg H: Nanoparticle-loaded macrophage-mediated photothermal therapy: Potential for glioma treatment. Lasers Med Sci. 30:1357–1365. 2015. View Article : Google Scholar : PubMed/NCBI
5	Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, Ligon KL, Greco SJ and Rameshwar P: Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget. 6:1190–1201. 2015. View Article : Google Scholar : PubMed/NCBI
6	Su Y, He Q, Deng L, Wang J, Liu Q, Wang D, Huang Q and Li G: MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s. Neuroreport. 25:12–17. 2014.PubMed/NCBI
7	Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
8	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
9	Jonas S and Izaurralde E: Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 16:421–433. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
11	Xia H, Ng SS, Jiang S, Cheung WKC, Sze J, Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 391:535–541. 2010. View Article : Google Scholar : PubMed/NCBI
12	Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, Zhuo Q, Zhang J and Wang W: miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep. 33:713–720. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yao J, Zhou E, Wang Y, Xu F, Zhang D and Zhong D: microRNA-200a inhibits cell proliferation by targeting mitochondrial transcription factor A in breast cancer. DNA Cell Biol. 33:291–300. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cong N, Du P, Zhang A, Shen F, Su J, Pu P, Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma. Oncol Rep. 29:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
15	Berthois Y, Delfino C, Metellus P, Fina F, Nanni-Metellus I, Al Aswy H, Pirisi V, Ouafik L and Boudouresque F: Differential expression of miR200a-3p and miR21 in grade II–III and grade IV gliomas: Evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther. 15:938–950. 2014. View Article : Google Scholar : PubMed/NCBI
16	Su Y, He Q, Deng L, Wang J, Liu Q, Wang D, Huang Q and Li G: MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s. Neuroreport. 25(12)2014.7. PubMed/NCBI
17	Ma CC, Xiong Z, Zhu GN, Wang C, Zong G, Wang HL, Bian EB and Zhao B: Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a. J Exp Clin Cancer Res. 35:902016. View Article : Google Scholar : PubMed/NCBI
18	Li N, Yang L, Wang H, Yi T, Jia X, Chen C and Xu P: MiR-130a and miR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One. 10:e01288862015. View Article : Google Scholar : PubMed/NCBI
19	Elhag R, Mazzio EA and Soliman KF: The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Anticancer Res. 35:1263–1269. 2015.PubMed/NCBI
20	Prieto-Vila M, Takahashi RU, Usuba W, Kohama I and Ochiya T: Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci. 18:E25742017. View Article : Google Scholar : PubMed/NCBI
21	Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X, Zhu Y and Yang P: The effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
22	Shi L, Chen J, Yang J, Pan T, Zhang S and Wang Z: MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352:255–264. 2010. View Article : Google Scholar : PubMed/NCBI